开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R581

References31

[1]	Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11: 615993. doi:10.3389/fendo.2020.615993 URL
[2]	Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy[J]. Ophthalmol Ther, 2020, 9(1): 21-33. doi:10.1007/s40123-019-00226-9 URL
[3]	Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy[J]. Thyroid, 2008, 18(3): 333-346. doi:10.1089/thy.2007.0315pmid:18341379
[4]	Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26. doi:10.1159/000443828pmid:27099835
[5]	Nicosia L, Reverberi C, Agolli L, et al. Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves’ ophthalmopathy[J]. Int J Endocrinol Metab, 2019, 17(1): e84427.
[6]	Aktaran S, Akarsu E, Erbaigci I, et al. Comparison of intravenous methylprednisolone therapyvs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy[J]. Int J Clin Pract, 2007, 61(1): 45-51. pmid:16889639
[7]	Kotwal A, Stan M. Current and future treatments for Graves’ disease and Graves’ ophthalmopathy[J]. Horm Metab Res, 2018, 50(12): 871-886. doi:10.1055/a-0739-8134 URL
[8]	Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(2): 432-441. doi:10.1210/jc.2014-2572 URL
[9]	Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(2): 422-431. doi:10.1210/jc.2014-3014 URL
[10]	Stan MN, Salvi M. Mangement of endocrine disease: rituximab therapy for Graves’ orbitopathy[J]. Eur J Endocrinol, 2017, 176(2): R101-R109. doi:10.1530/EJE-16-0552 URL
[11]	Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy[J]. Am J Ophthalmol, 2018, 195: 181-190. doi:S0002-9394(18)30431-8pmid:30081019
[12]	Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease[J]. J Clin Exp Ophthalmol, 2015, 6(2): 422.
[13]	Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy[J]. Nat Rev Endocrinol, 2020, 16(2): 104-116. doi:10.1038/s41574-019-0305-4pmid:31889140
[14]	Ju Y, Yang J. Teprotumumab for the treatment of thyroid eye disease[J]. Expert Rev Clin Immunol, 2020, 16(8): 739-743. doi:10.1080/1744666X.2020.1801421 URL
[15]	Rapoport B, McLachlan SM. Reflections on thyroid autoimmunity[J]. Horm Metab Res, 2018, 50(12): 840-852. doi:10.1055/a-0725-9297pmid:30357776
[16]	Tabasum A, Khan I, Taylor P, et al. Thyroid antibody-negative euthyroid Graves’ ophthalmopathy[J]. Endocrinol Diabetes Metab Case Rep, 2016, 2016: 160008.
[17]	Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway[J]. J Immunol, 2003, 170(12): 6348-6354. pmid:12794168
[18]	张荧钗, 徐书杭, 刘超. 胰岛素样生长因子Ⅰ受体及其在Graves眼病中作用研究进展[J]. 中华内分泌代谢杂志, 2020, 36(9): 799-802.
[19]	Łacheta D, Miéskiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy[J]. Biomed Res Int, 2019, 2019: 7453260.
[20]	Smith TJ. Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101383. doi:10.1016/j.beem.2020.101383 URL
[21]	Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease[J]. Am J Ophthalmol, 2019, 208: 281-288. doi:S0002-9394(19)30382-4pmid:31377284
[22]	Krieger CC, Neumann S, Gershengorn MC. Is there evidence for IGF1R-stimulating abs in Graves’ orbitopathy pathogenesis?[J]. Int J Mol Sci, 2020, 21(18): 6561. doi:10.3390/ijms21186561 URL
[23]	Krieger CC, Boutin A, Jang D, et al. Arrestin-β-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk[J]. Endocrinology, 2019, 160(6): 1468-1479. doi:10.1210/en.2019-00055 URL
[24]	Paik JS, Kim SE, Kim JH, et al. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy[J]. Immunobiology, 2020, 225(2): 151902. doi:10.1016/j.imbio.2019.151902 URL
[25]	Ju Y, Yang J. Teprotumumab for the treatment of thyroid eye disease[J]. Expert Rev Clin Immunol, 2020, 16(8): 739-743. doi:10.1080/1744666X.2020.1801421 URL
[26]	Ali F, Chorsiya A, Anjum V, et al. Teprotumumab (tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment[J]. Int Ophthalmol, 2021, 41(4): 1549-1561. doi:10.1007/s10792-021-01706-3 URL
[27]	Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy[J]. Br J Ophthalmol, 1998, 82(7): 773-779. doi:10.1136/bjo.82.7.773 URL
[28]	Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy[J]. N Engl J Med, 2017, 376(18): 1748-1761. doi:10.1056/NEJMoa1614949 URL
[29]	Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies[J]. Ophthalmology, 2021, 128(11): 1627-1651. doi:10.1016/j.ophtha.2021.04.024 URL
[30]	Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med, 2020, 382(4): 341-352. doi:10.1056/NEJMoa1910434 URL
[31]	Mishra S, Maurya VK, Kumar S, et al. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy[J]. Curr Eye Res, 2020, 45(11): 1325-1341. doi:10.1080/02713683.2020.1776331 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References31

Related Articles3

Recommended Articles

Metrics

Comments

[1]	GU Wei, HOU Liping, LI Xiaolong, GENG Jianlin.Effect of selenium yeast combined with vitamin D on thyroid-associated antibody levels in patients with Hashimoto thyroiditis at different ages[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 392-396.
[2]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 438-441.
[3]	FU Jiawen, LI Xiaohua, ZHANG Hongli, XU Yanhong, ZHU Yi.Study on the relationship between vitamin D deficiency and Hashimoto’s thyroiditis[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 27-31.